ALKS - Alkermes plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
51.905
-0.245 (-0.470%)
As of 10:19AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close52.150
Open52.060
Bid51.970 x 200
Ask52.020 x 300
Day's Range51.865 - 52.130
52 Week Range46.430 - 63.400
Volume212,693
Avg. Volume911,996
Market Cap7.982B
Beta2.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Surging Earnings Estimates Signal Good News for Alkermes (ALKS)
    Zacks6 days ago

    Surging Earnings Estimates Signal Good News for Alkermes (ALKS)

    Alkermes (ALKS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

  • GuruFocus.com8 days ago

    Primecap Management Buys Alkermes Biopharma

    Market-beating, media-shy firm picks biopharma with several drugs in final stages of approval

  • Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
    Zacks14 days ago

    Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

    The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Alkermes PLC NASDAQ/NGS:ALKS

  • Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal
    Zacks14 days ago

    Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

    While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

  • Barrons.com15 days ago

    Biogen's Next Big Drug Is…

    Shares of Biogen (BIIB) and Alkermes (ALKS) are both higher on Tuesday, after they announced a licensing agreement to develop and commercialize ALKS 8700, a multiple sclerosis treatment.  The drug, which ...

  • American City Business Journals15 days ago

    Recent lawsuits claim Alkermes fired female workers who complained of bias

    A drug vial inspector in Ohio who blew the whistle on alleged sexual harassment. A sales representative in Pennsylvania who complained that a male supervisor made derogatory comments about her weight and how she dressed. All three women worked for Alkermes (ALKS), a Waltham, Massachusetts-based drugmaker known for its drug to help opiate addicts that's one of the biggest life sciences employers in the state.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Why Is Alkermes (ALKS) Down 8.3% Since the Last Earnings Report?
    Zacks15 days ago

    Why Is Alkermes (ALKS) Down 8.3% Since the Last Earnings Report?

    Alkermes (ALKS) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?
    Investor's Business Daily16 days ago

    Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?

    Biogen will pay Alkermes up to $228 million to gain another multiple sclerosis asset as key drug Tecfidera faces a patent cliff in the mid-2020s.

  • Biogen Inc. Buys Its Way Out of Competition
    Motley Fool16 days ago

    Biogen Inc. Buys Its Way Out of Competition

    The big biotech gains rights to a potential Tecfidera competitor from Alkermes.

  • Barrons.com16 days ago

    Biogen: If You Can't Beat 'em…

    In its quest to keep one of its cash cows pumping, biotech giant Biogen (BIIB) has applied a simple lesson: If you can't beat 'em, partner with them. Biogen, of course, makes Tecfidera, a blockbuster treatment that is expected to go off patent sometime in the early 2020's. Leerink's Geoffrey Porges and Bradley Canino explain how the Alkermes deal might help: This morning Biogen issued a press release stating that they had entered into a global licensing agreement with Alkermes (MP) to develop ALKS 8700, a monomethyl fumarate (MMF) pro-drug that is currently in phase III development for relapsing-remitting multiple sclerosis (RRMS). This announcement comes as a surprise, since ALKS 8700 was presumed to be one of several rivals, and risks, to the outlook for Biogen’s Tecfidera.

  • TODAY'S CHARTS: Retailers pop on Cyber Monday; Time surges on Meredith deal
    Yahoo Finance16 days ago

    TODAY'S CHARTS: Retailers pop on Cyber Monday; Time surges on Meredith deal

    Meanwhile, retailers like Best Buy (BBY), Gap (GPS) and JCPenney (JCP) are trading higher on some positive early Black Friday results. JCPenney’s website saw the most visits of any day so far this year. Shares of Time Inc. (TIME) are surging after Meredith (MDP) said it struck a deal to buy Time for $1.85 billion in cash, with a little help from the Kochs.

  • Reuters16 days ago

    Biogen boosts multiple sclerosis holding with Alkermes license

    Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera. Biogen's deal to buy the rights to develop and market Alkermes' MS drug comes after the drugmaker in January licensed Danish company Forward Pharma A/S's drug patents covering the same condition for $1.25 billion. Sales of Tecfidera, Biogen's bestselling MS drug, has slowed amid stiff competition from Roche AG's Ocrevus and Sanofi SA's Aubagio.

  • The Wall Street Journal16 days ago

    Stocks to Watch: Amazon, Time, Alkermes, Biogen, SandRidge, Barracuda Networks

    Among the companies with shares expected to trade actively in Monday’s session are Amazon.com, Time, Alkermes, Lowe's and Walt Disney.

  • TheStreet.com16 days ago

    Alkermes Jumps on License Deal With Biogen -- Biotech Movers

    Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

  • MarketWatch16 days ago

    UPDATE: Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership

    Alkermes PLC shares rose 5.8% in premarket trade Monday on news of the company's partnership with Biogen Inc. on the multiple sclerosis drug ALKS 8700. Biogen shares were not active in premarket trade. ...

  • Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : November 27, 2017
    Capital Cube16 days ago

    Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : November 27, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alkermes Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Investopedia26 days ago

    Why Biotech Sage Therapeutics Is Overvalued

    Sage's stock soared after it reported promising clinical results for its postpartum depression drug.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit26 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Alkermes PLC NASDAQ/NGS:ALKS

  • Investopedia28 days ago

    Biotech Alkermes Could Jump On Opioid Treatment Sales

    The company's sales could explode it its opioid treatment is successful

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit29 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on October 24. Index (PMI) data, output in the Healthcare sector is rising.

  • American City Business Journalslast month

    Kamala Harris investigates opioid addiction drug

    Alkermes, one of Massachusetts' largest life sciences firms, came under fire this summer following reports about its aggressive sales practices for an opioid addiction drug. Now the company is facing an investigation by a prominent U.S. senator accusing it of profiting from a nationwide crisis. Kamala Harris, a Democrat from California, said Monday that she has launched an investigation into Alkermes (ALKS), which has around 650 employees in Waltham, Mass. The probe focuses on the company’s practice of marketing Vivitrol directly to judges and corrections officers — rather than to physicians — as a treatment for inmates and parolees with opioid addiction.

  • Cramer's lightning round: Auto stocks like GM are not my ...
    CNBC Videos2 days ago

    Cramer's lightning round: Auto stocks like GM are not my ...

    Jim Cramer raced through his take on callers' favorite stocks, including one in the auto sector.